1 insider has bought $54k of Indivior Pharmaceuticals, Inc. shares across 1 disclosed dealing since August 2026.
| Aug 5, 2026 | Anderson Woodrow D — Chief Accounting Officer | $54,420 |
Indivior Pharmaceuticals, Inc. is classed as health care. By value disclosed, that ranks 41st of the 44 health care companies where insiders bought in the last twelve months.
Companies with a comparable amount of disclosed buying: MSA Safety Inc · PALISADE BIO, INC. · electroCore, Inc. · Anixa Biosciences Inc · Amylyx Pharmaceuticals, Inc. · Aclarion, Inc.
See also the biggest buys, cluster buying and the most-active companies.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Every row is a public regulatory disclosure — a Form 4 filing with the SEC — collected within minutes of being published. We don’t take company submissions and we don’t edit the numbers; the only thing we add is the rating and the reasoning behind it.
Sometimes. A insider buying with their own money is one of the few honest signals in the market, but plenty of purchases are routine — small top-ups, scheme allocations, or a well-paid executive rounding out a holding. That’s what our six-point check is for: it separates the conviction buys from the housekeeping, and shows you which is which.
The pipeline runs every 15 minutes through the trading day, so a new disclosure appears here shortly after it’s filed. Company stats refresh daily.
Yes — that’s what the app is for. Follow Indivior Pharmaceuticals, Inc. and you’ll get a push the moment a insider files, with the full analysis attached, plus alerts if the price moves after a buy you’re following.
No. ddbx rates the conviction behind insider buys and shows the reasoning. It’s information, never a recommendation, and never a guarantee. What you do with it is your call.